Chemistry:CYB005

From HandWiki

CYB005, or CYB-005, also known as deuterated phenethylamine derivative, is a serotonin receptor agonist and serotonergic psychedelic which is under development for use at non-hallucinogenic doses in the treatment of psychiatric disorders and neuroinflammation.[1][2][3]

Interactions

Pharmacology

Pharmacodynamics

CYB005 acts as a serotonin receptor agonist and is a serotonergic psychedelic.[1][3] In addition, CYB005 may also inhibit serotonin and dopamine reuptake.[3]

Chemistry

It is a phenethylamine derivative and a deuterated compound.[1][2][3] The exact chemical structure of CYB005 does not yet seem to have been disclosed.[1][3] However, it appears to be closely related to CYB210010, which itself is non-deuterated.[4][5][6] In addition, CYB005's developer has patent protection for the compound, indicating that its chemical structure has been published in the patent literature.[1][4][7]

Development

As of October 2024, CYB005 is in the research or preclinical stage of development.[1][2] It has been in this developmental stage since at least 2022.[3] The drug is under development by Cybin.[1][2][3] Other related drugs include the deuterated tryptamines CYB003 and CYB004.[3][8]

See also

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 "CYB 005". 28 October 2024. https://adisinsight.springer.com/drugs/800064373. "CYB 005 is a phenethylamine derivative is being developed by Cybin for the treatment of treatment resistant psychiatric disorders." 
  2. ↑ 2.0 2.1 2.2 2.3 "Delving into the Latest Updates on CYB-005 with Synapse". 1 November 2024. https://synapse.patsnap.com/drug/a8134884163c4d42b7817e7986708a88. 
  3. ↑ 3.0 3.1 3.2 3.3 3.4 3.5 3.6 3.7 "Key Characteristics and Development of Psychoceuticals: A Review". Int J Mol Sci 23 (24). December 2022. doi:10.3390/ijms232415777. PMID 36555419. "Table 1. Biochemical structures, mechanisms, and receptor functions of twenty psychoceutical drugs.: [...] Drug Name: Phenethylamine derivative (CYB005): Chemical Structure: *. Target type: –. Method of Action: CYB005 inhibits serotonin and dopamine transporters within the synaptic cleft. [...] These drugs generally bind to CNS G-protein receptors within the 5-HT family, such as 5-HT1A, 5-HT2A, and 5-HT2B, and act agonistically [9,13–15,17,18]. Additionally, two of these, ecstasy and CYB005 (phenethylamine derivative [20]), block the reuptake of serotonin, increasing the serotonin levels within the synaptic cleft [12,21,22]. [...] According to preclinical data, CYB005, a phenethylamine derivative, aims to inhibit serotonin transporters within the synaptic cleft [20–22]. [...] Studies on [...] CYB005 [...] were not found in the literature search, so this information was obtained through the websites of their respective pharmaceutical companies. [...] Table 2. Highlights of the psychoceutical benefits.: Drug: CYB005 (Phenethylamine derivative). Benefit: Treats neuroinflammation and psychiatric conditions. [...] Three [deuterated] drugs that researchers have been working on are [...] CYB005 (for neuroinflammation). [...] Finally, CYB005 is a phenethylamine derivative currently in preclinical development [55], which has the potential to treat neuroinflammation and psychiatric conditions [20]. [...] Of the 20 drugs, [...] CYB005 [...] do not currently have completed clinical trials.". 
  4. ↑ 4.0 4.1 "Cybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines Program". 24 October 2024. https://finance.yahoo.com/news/cybin-announces-grant-first-u-113000913.html. 
  5. ↑ "Synthesis and Structure-Activity Relationships of 2,5-Dimethoxy-4-Substituted Phenethylamines and the Discovery of CYB210010: A Potent, Orally Bioavailable and Long-Acting Serotonin 5-HT2 Receptor Agonist". J Med Chem 67 (8): 6144–6188. April 2024. doi:10.1021/acs.jmedchem.3c01961. PMID 38593423. 
  6. ↑ "ACNP 62nd Annual Meeting: Poster Abstracts P251 – P500: P405. Discovery and Preclinical Characterization of the Phenylalkylamine, CYB210010, a Potent and Long-Acting Serotonin 5-HT2A Receptor Agonist". Neuropsychopharmacology 48 (Suppl 1): 211–354 (299–299). December 2023. doi:10.1038/s41386-023-01756-4. PMID 38040810. 
  7. ↑ "Therapeutic phenethylamine compositions and methods of use". 18 August 2021. https://patents.google.com/patent/US12122741B2/. 
  8. ↑ "Next-generation psychedelics: should new agents skip the trip?". Nat Biotechnol 42 (6): 827–830. June 2024. doi:10.1038/s41587-024-02285-1. PMID 38831049. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:CYB005&oldid=4027788"